Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
| Autor: | Casadei-Gardini A., Dadduzio V., Rovesti G., Cabibbo G., Vukotic R., Rizzato M. D., Orsi G., Rossi M., Guarneri V., Lonardi S., D'agostino D., Celsa C., Andreone P., Zagonel V., Scartozzi M., Cascinu S., Cucchetti A. |
|---|---|
| Přispěvatelé: | Casadei Gardini, A., Dadduzio, V., Rovesti, G., Cabibbo, G., Vukotic, R., Rizzato, M. D., Orsi, G., Rossi, M., Guarneri, V., Lonardi, S., D'Agostino, D., Celsa, C., Andreone, P., Zagonel, V., Scartozzi, M., Cascinu, S., Cucchetti, A., Casadei-Gardini A., Dadduzio V., Rovesti G., Cabibbo G., Vukotic R., Rizzato M.D., Orsi G., Rossi M., Guarneri V., Lonardi S., D'agostino D., Celsa C., Andreone P., Zagonel V., Scartozzi M., Cascinu S., Cucchetti A. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
macro-vascular portal vein invasion
Male Carcinoma Hepatocellular Antineoplastic Agents extra hepatic disease and BCLC survival NLR Antineoplastic Agent Cohort Studies alpha-fetoprotein Humans Lymphocyte Count Survivors prognostic factor Aged Liver Neoplasms Middle Aged Sorafenib Progression-Free Survival Italy Liver Neoplasm hepatitis C Female Cohort Studie Carcinoma Hepatocellular ...Liver Neoplasms Human |
| Popis: | Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional survival of patients without disease progression highlights that NLR and ECOG are the factors that most accurately predict the probability of long survival. The 3-year conditional survival of patients with disease progression showed a medium effect size for HCV status, alpha-fetoprotein and NLR at all time-points. Macro-vascular portal vein invasion, extra hepatic disease, and BCLC we have a large effect size at 6 months and a medium effect size at 12 and 24 months.Our findings support the use of baseline NLR for the identification of patients with a higher probability of long-survival. NLR should be used as a stratification factor in the forthcoming clinical trials on the drugs for the advanced HCC now in pipeline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|